Chair:
Professor Giuseppe Saglio (Italy)
Management Practicalities
Co-chair:
Professor Mohammed Yassin (Qatar)
Overview
The practicalities of CML management are key. The 9 topics in this module only cover some of these. If you have topics you would like to see discussed please contact us at info@cml-foundation.org.
Arlene Harriss-Buchan, iCMLf Program Manager
Index
Click to jump to section
1. Managing Intolerances – Perspectives from the real world
2. Managing Comorbidities – Hepatitis B
3. Managing Comorbidities – Obesity
4. Managing Comorbidities – Tuberculosis
5. Managing Comorbidities – Opthalmologic manifestations
6. Nature and Incidence of Adverse Events
7. TKI interactions with Concomitant Medication
8. Generic TKI’s
9. Allogenic Transplantation in CML
Managing intolerances – Perspectives from the real world
Dr Massimo Breccia
Az. Policlinico Umberto I
Sapienza University
Rome, Italy
Managing comorbidities – Hepatitis B reactivation
Dr Mohamed A Yassin
Senior Consultant Hematologist, NCCCR
Associate Professor of Medicine, CMED-QU
Doha, Qatar
Managing comorbidities – Managing obesity
Dr Mohamed A Yassin
Senior Consultant Hematologist, NCCCR
Associate Professor of Medicine, CMED-QU
Doha, Qatar
Managing Comorbidities – Association of Tuberculosis in Patients with CML
Dr Mohamed A Yassin
Senior Consultant Hematologist, NCCCR
Associate Professor of Medicine, CMED-QU
Doha, Qatar
Managing comorbidities – Opthalmologic manifestations
Dr Mohamed A Yassin
Senior Consultant Hematologist, NCCCR
Associate Professor of Medicine, CMED-QU
Doha, Qatar
TKI Interactions with Concomitant Medication
Dr Katerina Machova Polakova
Institute of Hematology and Blood Transfusion and
1st Faculty of Medicine,
Charles University
Prague, Czech Republic
Nature and Incidence of Adverse Events
Dr Valentín García Gutiérrez
Department of Hematology and Hematherapy
Hospital Universitario Ramón y Cajal
Universidad de Alcalá
Madrid, Spain
Generic TKIs - Giving your patient the most effective and safe usage
Dr Jeff Lipton
University of Toronto and
Princess Margaret Cancer Centre
Toronto, Canada
When to Consider Allogenic Transplantation in CML
Dr Jerry Radich
Clinical Research Division
Kurt Enslein Endowed Chair
Fred Hutch
Seattle, USA
When to consider allogenic transplantation in CML
Dr Guillermo J Ruiz Arguelles
Center for Hematology and Internal Medicine
Clinica Ruiz
Puebla, Mexico
Discussion
Do you have any questions, or comments for the speakers, or community?
Leave your comments below and we will contact the presenter for a reply.
To prevent spam all comments will be forwarded to an admin who will approve the comments and arrange a reply if appropriate.
Subscribe
0 Comments